Acute pancreatitis: the substantial human and financial costs

Area of Science:

• Gastroenterology and Critical Care Medicine

Background:

• Hospital mortality for acute pancreatitis has decreased from 25-30% to 6-10% over 30 years due to improved understanding and radiological imaging.
• Severe acute pancreatitis involves a systemic inflammatory response syndrome (SIRS), a critical phase where multiple organ failure and death can occur.

Purpose of the Study:

• To explore strategies for further reducing mortality and morbidity in acute pancreatitis.
• To evaluate the potential of novel therapeutic agents and centralized management models.

Main Methods:

• Review of natural history and radiological advancements in acute pancreatitis management.
• Discussion of the role of systemic inflammatory response syndrome (SIRS) and potential interventions.
• Consideration of prophylactic antibiotics, surgical interventions, and pharmacological agents like platelet-activating factor (PAF) antagonists.

Main Results:

• Survival into the second phase of pancreatitis may involve local complications like infected pancreatic necrosis, treatable with antibiotics and surgery.
• Agents such as lexipafant, a PAF antagonist, show potential in reducing multiple organ failure and associated costs.
• Centralization of severe acute pancreatitis patient management in specialized units is proposed for improved outcomes.

Conclusions:

• Continued improvements in acute pancreatitis care rely on a comprehensive approach including early recognition of SIRS, judicious use of antibiotics and surgery, and potentially novel pharmacological agents.
• Centralizing care in expert units is crucial for effectively managing this complex disease and optimizing patient survival and quality of life.